Arabic Arabic English English French French German German
dark

Relief Therapeutics Provides Update on Regulatory Interactions in the United Kingdom and European Union Relating to Lead Drug Candidate, RLF-100 (Aviptadil)

RELIEF THERAPEUTICS Holding SA reported that it has received scientific advice from the Medicines and Healthcare products Regulatory Agency in the United Kingdom relating to its lead investigational drug, RLF-100 TM, for the treatment of respiratory deficiency due to severe COVID-19. Read More

Total
0
Shares
Leave a Reply

Your email address will not be published. Required fields are marked *

Previous Post

SQI Diagnostics Appoints Andrew Morris as Chief Executive Officer, and Grants Options

Next Post

Dynavax Provides Update on its COVID-19 Collaboration with Valneva

Related Posts
Total
0
Share